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Abstract Osteosarcoma is the most common primary
malignant bone tumor, accounting for approximately 20%
of all primary sarcomas in bone. Although treatment
modalities have been improved over the past decades, it is
still a tumor with a high mortality rate in children and
young adults. Based on histological considerations, osteo-
sarcoma arises from impaired differentiation of these
immature cells into more mature types and that correction
of this impairment may reduce malignancy and increase the
efficiency of chemotherapy. The purpose of this study was
to determine the effect of specific inhibitors of MAPK
extracellular signaling-regulated kinase (ERK) kinase
(MEK) and p38 on the differentiation of human osteosar-
coma cell line SaOS-2 cells. We found that PD98059, a
specific inhibitor of MEK, inhibited the serum-stimulated
proliferation of SaOS-2 cells; whereas SB203580, a
specific inhibitor of p38 MAPK, had little effect on it.
SB203580 suppressed ALPase activity, gene expression of
type I collagen, and expression of ALP and BMP-2
mRNAs; whereas PD98059 upregulated them dose depen-
dently. In addition, immunoblot and immunostaining
analysis revealed that phosphorylation of ERK was in-
creased by treatment with SB203580; whereas PD98059
increased the phosphorylation of p38, which implies a
seesaw-like balance between ERK and p38 phosphoryla-
tion. We suggest that osteosarcoma cell differentiation is
regulated by the balance between the activities of the ERK
and p38 pathways and that the MEK/ERK pathway
negatively regulates osteosarcoma cell differentiation,
whereas the p38 pathway does so positively. MEK inhibitor
may thus be a good candidate for altering the expression of
the osteosarcoma malignant phenotype.
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Background
Osteosarcoma is the most frequent primary bone tumor
(Goorin et al. 1985), and it has a marked tendency to recur
and metastasize to the lungs and skeleton (Lane et al.
1986). It originates from undifferentiated mesenchymal
cells and consists of osteoblastic, chondroblastic, and
fibroblastic cells or their combination. These histologic
features suggest that osteosarcoma arises from impaired
differentiation of these immature cells into more mature
types and that correction of this impairment may reduce
malignancy and increase the efficiency of chemotherapy.
Therefore, differentiation induction holds great potential as
a new modality of cancer therapy (Hozumi 1983).
Mitogen-activated protein kinases (MAPKs) are proline-
directed serine–threonine kinases that have important func-
tions as mediators of cellular responses to a variety of
extracellular stimuli (Cano and Mahadevan 1995; Marshall
1995). Extracellular zsignal-regulated kinases (ERKs) are
characteristically activated by various growth factors. Mem-
bers of the p38 MAPK (p38) and c-Jun N-terminal kinase
(JNK) subfamilies are strongly activated in response to stress
stimuli (Raingeaud et al. 1995; Kyriakis et al. 1994) and thus
proinflammatory cytokines, and have been given the name
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stress-activated protein kinases (SAPKs). Whereas the ERK
pathway is usually associated with cell proliferation and
protection from apoptosis, p38 and JNK ones can promote
apoptosis in many systems (Xia et al. 1995). Recent studies
suggest that, in addition to its effect on apoptosis, the p38
pathway might also be involved in the differentiation of
neural cells (Iwasaki et al. 1999), adipocytes (Engelman
et al. 1998), and chondrocytes (Yoshimichi et al. 2001;
Shimo et al. 2005). In osteoblast-like cells, activation of
ERK has been reported in response to several growth factors
including mitogens acting through receptor tyrosine kinases
(RTKs) such as basic fibroblast growth factor (bFGF; Suzuki
et al. 2000), epidermal growth factor (EGF; Matsuda et al.
1998), platelet-derived growth factor (PDGF; Chaudhary and
Avioli 1997), and insulin-like growth factor-1 (IFG-1;
Kawane and Horiuchi 1999). As reported to be its effect in
other cell systems, activation of ERK in osteoblast-like cells
by growth factors is associated with enhanced cell prolifer-
ation. However, recent data have suggested that ERK might
also be involved in the regulation of bone cell differentiation
(Kawamura et al. 1999; Tokuda et al. 1999). Whereas studies
using MC3T3-E1 cells suggest that activation of p38 is
critical for ALP expression induced by fetal bovine serum
(Suzuki et al. 2002). Differentiation of the bone marrow
osteoprecursors was also inhibited in terms of ALP by a p38
inhibitor (Hu et al. 2003). In the present study, we
investigated the effect of specific inhibitors of MEK and
p38 on the differentiation of SaOS-2 cells and found that the
MEK inhibitor enhanced and accelerated the differentiation
but that the p38 inhibitor suppressed it. In addition we
observed a seesaw-like phosphorylation between ERK and
p38 when the cells were treated with the inhibitor for MEK
or p38.
Results
Effect of ERK and p38 MAPK inhibitors
on the proliferation of SaOS-2 cells
Growth factors contained in FBS have been shown to play
a critical role in the growth and differentiation of SaOS-2
cells (Bruserud et al. 2005). It is well documented that
many growth factors can lead to the stimulation of different
MAP kinases. To determine whether activation of ERK was
required for serum-stimulated SaOS-2 cell proliferation, we
incubated SaOS-2 cells in fresh αMEM+10% FBS in the
presence of the ERK-specific MEK1/2 inhibitor PD98059
(20 μM; Williamson et al. 2004). This inhibitor blocked the
serum-stimulated proliferation of the cells; whereas incu-
bation with the specific p38 inhibitor, SB203580 (Bebien
et al. 2003), at 20 μM had little effect on the up-regulation
of proliferation by serum (Fig. 1a).
Inhibition of ERK stimulated ALPase activity
in SaOS-2 cells
To determine whether activation of ERK and p38 was
required for SaOS-2 cell differentiation, we stimulated
SaOS-2 cells with fresh αMEM+10% FBS in the presence
of 10 or 20 μM PD98059 or SB203580 for 48 h. Treatment
with SB203580 inhibited the ALPase activity dose depen-





















































































































Fig. 1 Effects of MAPK inhibitors on SaOS-2 cell proliferation
alkaline phosphatase activities and mineralization. a For the [3H]
thymidine incorporation assay, cells were cultured with 10 or 20 μM
PD98059 or SB203580 for 18 h, and the assay was performed as
described under Materials and methods. b For the ALPase activity
assay, cells were cultured with 10 or 20 μM PD98059 or SB203580
for 48 h, and the activity was determined as indicated in Materials and
methods. c Photographs of bone nodules formation in 24-well
multiplates. The data from a typical experiment are presented; similar
results were obtained in 3 separate experiments. Asterisks indicate
significant difference of *p<0.05 and **p<0.01
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presence of PD98059 at 20 μM was up-regulated (Fig. 1b),
which concentration is sufficient to inhibit the ERKs in
calvarial osteoblasts (Li et al. 2002) and SaOS-2 cells
(Juretic et al. 2001).
Effect of ERK and p38 MAPK inhibitors
on the mineralization of SaOS-2 cells
To investigate whether activation of ERK and p38 was
required for formation of mineralized bone nodules by
SaOS-2 cells, these cells treated with 20 μM PD98059 or
SB203580 were cultured in the presence of 50 μg/ml
ascorbic acid and 10 mM β-glycerophosphate (β-GP) for
10 days. SaOS-2 cells treated with PD98059 showed
marked mineralization, whereas SB203580 treated cells
mineralization was inhibited compared to the control
culture (Fig. 1c).
MEK inhibitor enhanced and accelerated
the differentiation in SaOS-2 cells
To determine whether activation of ERK and p38 was
required for the early to late stage of SaOS-2 cell
differentiation, we compared the mRNA expression of type
I collagen, ALP, and osteocalcin in the presence of
PD98059 or SB203580 with that in fresh 10% FBS culture
medium. PD98059 up-regulated type I collagen, ALP, and
osteocalcin mRNA levels dose dependently; whereas
increasing amounts of SB203580 suppressed those of type
I collagen, ALP, and osteocalcin (Fig. 2a–c), indicating that
activation of ERK inhibited early and late stages of SaOS-2
cell differentiation, whereas p38 stimulated them. However,
type I collagen, ALP, and osteocalcin mRNA expression
were not changed by PD98059 or SB203580 in the absence
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Fig. 2 Effect of MAPK inhibitors on the differentiation marker
mRNAs in SaOS-2 cells. SaOS-2 cells were cultured for 7 days in
complete αMEM containing 10% FBS. Then, the cells were changed
with or without fresh αMEM+10% FBS culture medium and then
incubated for 12 h. Thereafter the cells were treated with PD98059 or
SB203580 for 24 or 48 h; and their total RNA was analyzed by real-
time RT-PCR for type I collagen (a), ALP (b), osteocalcin (c), and
BMP-2 (d) mRNA. The data from a typical experiment are presented;
similar results were obtained in 3 separate experiments. Asterisks
indicate significance at *p<0.05 and **p<0.01. The house-keeping
gene GAPDH served as an internal control
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are members of transforming growth factor-β (TGF-β)
family that play essential role in osteogenesis (Urist 1965).
Treatment with 20 μM PD98059 for 24 or 48 h up-
regulated BMP-2 mRNA expression, whereas that with
SB203580 suppressed it (Fig. 2d).
Cross-talk between ERK and p38
New at al. (New et al. 2001) recently reported similar
results; i.e., they observed the enhancement of ERK
phosphorylation by treatment with SB203580 in PC12
cells in the presence of epidermal growth factor (EGF).
Their finding prompted us to investigate the possibility of
cross-talk between ERK and p38. Phosphorylation of ERK
and p38 was increased 12 h after changing the culture
medium to fresh αMEM containing 10% FBS (Fig. 3a).
SaOS-2 cells were incubated with various concentrations of
PD98059 or SB203580 in the presence of fresh αMEM
containing 10% FBS and subjected to immunoblot analysis
with anti-phospho-ERK and anti-phospho-p38. The phos-
phorylation of ERK was markedly decreased by PD98059
but clearly increased in the presence of SB203580, both
time and dose dependently (Fig. 3b and c). On the other
hand, phosphorylation of p38 was markedly suppressed by
SB203580 but up-regulated in the presence of PD98059, in
a time and dose-dependent manner (Fig. 3d and e). As
shown in Fig. 4, the expression of phosphorylated ERK
was markedly decreased by PD98059 (Fig. 4e) but
markedly increased by SB203580 (Fig. 4f). On the other
hand, the phosphorylation of p38 was suppressed by
SB203580 (Fig. 4j) but up-regulated by PD98059
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Fig. 3 Possible cross-talk between ERK and p38. a SaOS-2 cells
were cultured for 7 days in complete α MEM containing 10% FBS.
Then, the cells were either kept in the same medium or changed with
fresh αMEM+10% FBS; and 12 h later the cells were subjected to
immunoblotting using anti-p-ERK or anti-p-p38. b–f SaOS-2 cells
were cultured for 7 days in complete αMEM containing 10% FBS.
Then, the cells were either kept in the same medium (b) or changed
with fresh αMEM+10% FBS culture medium (c–f); and 12 h later
they were then treated with 20 μM PD98059 or SB203580 for the
indicated times (c and e) or with various concentrations of PD98059
or SB203580 for 60 min (d and f). Cell lysate were processed for
immunoblot determination of total ERK (c and d) and total p38 (e and
f) or levels of phosphorylated ERK (c and d) and p38 (e and f), which
are indicated as p-ERK and p-p38, respectively. The data from a
typical experiment are presented; similar results were obtained in 3
separate experiments
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influence p38 and ERK closs-talk activation, respectively,
in the absence of serum (Fig. 3b). Taken together, our data
show that the p38 inhibitor increased the phosphorylation
of ERK, and the MEK inhibitor increased that of p38 in
compete culture medium containing 10% FBS.
Discussion
In this report, the effects of MEK and p38 inhibitors on the
differentiation of SaOS-2 cells were investigated. The MEK
inhibitor markedly enhanced differentiation in the presence
of serum, whereas the p38 inhibitor suppressed it. Activation
of these signaling pathways in differentiating SaOS-2 cells
after addition of fresh culture medium containing 10% FBS
is mediated by factors contained in the serum, because no
stimulation of these MAPKs was detected when fresh culture
medium containing no FBS was used (data not shown). The
serum factors responsible for the stimulation of these
MAPKs in osteosarcoma cells are not known, but are likely
ligands for different types of receptors such as RTKs,
G-protein-coupled receptors, and possibly cytokine recep-
tors. Because chemical inhibitors of signal transduction are
powerful tools to explore signaling pathways, their use has
become more widespread to investigate what pathways are
involved in cell responses such as growth and differentiation.
Osteosarcoma cells at different osteoblastic stages
display many of the features of differentiated osteoblasts,
and the signal transduction pathway for osteosarcoma
differentiation has been studied. Several research groups
have investigated the involvement of MAPKs in this
signaling pathway (Suzuki et al. 2002; Hu et al. 2003).
As mentioned earlier, ERK is activated by growth factors
acting through different types of receptors and mediates
their mitogenic effects in bone-forming cells. As expected
from this information, inhibiting the stimulation of ERK in
response to FBS in proliferating SaOS-2 cells stopped their
[3H] thymidine incorporation (Fig. 1a), thus confirming the
importance of this pathway in regulating SaOS-2 cell
proliferation. We also demonstrated that ERKs played a
negative role in serum-induced SaOS-2 cell differentiation.
Blockage of MEK1/2 with the specific inhibitor PD98059
had a significant promotive effect on SaOS-2 cell differen-
tiation. Our results are not in agreement with the findings
that expression of dominant-negative ERK1 inhibited not
only human osteoblast differentiation, but also proliferation,
cell spreading, and migration (Lai et al. 2001). One
explanation for the discrepancy is the cell source. Osteo-
blasts isolated from human bone chips were used in the
experiments just cited, whereas we used a human osteosar-
coma cell line. Another possibility is the difference between













Fig. 4 Expression of phosphorylated forms of ERK and p38 in SaOS-
2 cells. (a–l) SaOS-2 cells were cultured for 4 days in complete
αMEM containing 10% FBS, and then the medium was changed to
fresh αMEM+10% FBS for 12 h, after which the cells were treated
with vehicle (a–d), 20 μM PD98059 (e–h), or SB203580 (i–k) for
60 min. The cells were immunostained for phosphorylated ERK (a, e,
and i) phosphorylated p38 (b, f, and j) and DAPI (c, g, and k) and
then photographed under a microscope. d, h, and l: merged image of
phase-contrast microscopic views in “a–c”, in “e–g” and in “i–k”
respectively. Bar: 50 μm
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Dominant-negative ERK1 suppressed the cellular differen-
tiation, whereas PD98059 accelerated it. It is likely that
PD98059 positively affected the p38 signaling pathway-
induced differentiation. Possible “seesaw-talk” between
ERK and p38 signals may be proposed, which is discussed
later on herein.
On the other hand, inhibition of p38 by its specific
inhibitor, SB203580, interfered with the differentiation
process of SaOS-2 cells. All of the differentiation markers,
including type 1 collagen, ALP, and osteocalcin mRNAs,
were reduced in the presence of the p38 inhibitor. These
data suggest that activation of p38 is necessary for SaOS-2
cell differentiation. This suggestion is further supported by
the fact that p38 MAPK is activated at the early stage of
osteoblast differentiation (Suzuki et al. 2002). Furthermore,
inhibition of p38 activity was associated with a slight
increase in SaOS-2 cell proliferation, indicating that the p38
pathway is probably not involved in mediating the growth
arrest that precedes the onset of SaOS-2 cell differentiation.
However, inhibition of JNK by SP600125 was not
associated with ALP and osteocalcin mRNAs when fresh
culture medium containing 10% FBS was used (data not
shown). Indeed, SP600125 could not mediate the ALP and
osteocalcin production in normal culture condition, but
associated with small effects on ALP, and a marked and
consistent decrease in osteocalcin production in response to
BMP-2 in both MC3T3-E1 and calvaria cells (Guicheux et
al. 2003). Taken together, these observations indicate that
the JNK is implicated in BMP-2-induced osteoblastic cell
differentiation with distinct regulatory effects on ALP and
OC expression.
SaOS-2 cell differentiation is stimulated by local factors
such as BMPs (Huang et al. 2002). Inhibition of p38 caused
a delay in SaOS-2 cell differentiation. This delay may be
partially released by the presence of BMP-2, suggesting
that BMP-2 is able to overcome the loss of signals from
p38 during SaOS-2 cell differentiation. Activation of p38
by BMP-2 is involved in ALP and osteocalcin expression
(Guicheux et al. 2003). BMPs control osteoblast differen-
tiation through Smad proteins that are inhibited by Tob
(Yoshida et al. 2000). Activation of the BMP-Smad
pathway may somehow compensate for the loss of p38.
Further experiments will be needed to investigate the
mechanism.
Immunoblot analysis using antibodies against phos-
phorylated MAP kinases revealed a “seesaw-talk” between
ERK and p38: i.e., the MEK inhibitor caused a decrease in
the level of phosphorylated ERK with an increase in that of
phosphorylated p38, whereas the p38 inhibitor had the
opposite effects. A similar seesaw cross-talk was previously
reported, in which SB203580 by itself did not affect the
activity of ERK but significantly extended EGF-induced
ERK activation in PC12 cells (New et al. 2001). In
RAW264.7 cells, seesaw-like phosphorylation between
ERK and p38 was observed when the cells were treated
with inhibitors for MEK and p38 in the presence of
RANKL (Bruserud et al. 2005). It is unlikely that
secondary products derived from transcripts by transcrip-
tion factors downstream of a MAPK pathway affected the
other MAPK pathway, because the enhancement of phos-
phorylation by MAPK inhibitors took place after only
30 min. Previous studies have shown that SB203580
inhibits Raf production but paradoxically stimulates Raf
activity (Hall-Jackson et al. 1999). This phenomenon could
be due to a negative-feedback mechanism by which Raf
inhibits itself. It is also known that SB239069, another
highly selective p38 inhibitor, which does not inhibit Raf
(Underwood et al. 2000), also increased H2O2-stimulated
ERK phosphorylation (Liu and Hofmann 2004). Thus it is
thus unlikely that the effect of SB203580 on ERK
phosphorylation was due to its effect on Raf. A recent
study demonstrated that activation of p38 can block the
ERK pathway at the level of MEK through activation of
protein phosphatase 2A (pp2A; Westermarck et al. 2001).
Furthermore, SB203580 enhanced H2O2-stimulated ERK
phosphorylation via pp2A in cardiac ventricular myocytes
(Liu and Hofmann 2004). On the other hand, MAPK
phosphatase (MKP)-1 is known to be up-regulated by ERK
and to preferentially inactivate p38. PD98059 enhanced
lipopolysaccharide-stimulated, p38 phosphorylation via
MKP-1 in Raw 264.7 cells (Hotokezaka et al. 2002). Such
findings may not be directly linked to the results in this
study, but suggest the possibility that the chemical
inhibitors may affect more than one molecule.
In conclusion, MEK inhibitor PD98059 suppressed
serum-induced proliferation and up-regulated the differen-
tiation of osteosarcoma cells. Further studies are needed to
clarify the reciprocal effects of MAPK inhibitors on
differentiation in SaOS-2 cells (Fig. 5) and to elucidate
the seesaw cross-talk mechanism by which the inhibition of
ERK or p38 phosphorylation by MEK or p38 inhibitors











Fig. 5 Scheme showing the seesaw cross-talk, between MEK/ERK
and p38 pathways during the differentiation of Saos-2 cells. Growth
factors contained in FBS activate both ERK and p38 pathways. The
MEK/ERK pathway suppresses differentiation and is inhibited by
PD98059. In contrast, the p38 pathway enhances differentiation and is
inhibited by SB203580. PD98059 inhibits ERK and activates p38,
whereas SB203580 inhibits p38 and activates ERK
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Materials and methods
Materials
The alpha modification of Eagle’s medium (αMEM) was
purchased from Invitrogen Corporation (Grand Island, NY);
and fetal bovine serum (FBS), from JRH Bioscience
(Lenexa, KS). Plastic dishes and plates were from Becton
Dickinson (Frabkin Lakes, NJ). P-nitrophenyl phosphate
(p-NPP) and p-nitrophenol (p-NP) were purchased from
Wako Pharmaceuticals (Osaka, Japan). [3H] Thymidine was
obtained from Amersham Pharmacia Biotech (Aylesbury,
UK). PD98059 and SB203580 came from Calbiochem
(La Jolla, Ca). Anti-ERK1/2, p-ERK1/2, p38 and p-p38
antibodies were purchased from Santa Cruz Biotechnology
(Santa Cruz, CA).
Cell culture
Human osteosarcoma cell line SaOS-2 cells were inocu-
lated at a density of 1×106 cells/60-mm-diameter dish,
2×105 cells/ well in 12-well multiplates, and 2×104 cells/
well in 96-well multiplates. These cells were cultured in
αMEM containing 10% FBS. All cells were cultured in
5% CO2 in an atmosphere of 37°C.
[3H] thymidine incorporation assay
The proliferation of SaOS-2 was assessed by measuring the
incorporation of [3H] thymidine into the cells. SaOS-2 cells
(1×104) were cultured in 96-well plates under the conditions
described in the figure legends and were pulsed with [3H]
thymidine (1 μCi/ ml of medium) for 4 h during incubation
with test agents. The radioactivity incorporated into acid-
precipitated material was counted by use of a microbeta
scintillation counter (Micro Beta-PLUS; WALLAC).
Alkaline phosphatase activity
For estimation of ALPase activity, SaOS-2 cells was grown
to confluence in 24-well multiplates with αMEM contain-
ing 10% FBS. Then the cells were either kept in the same
medium or the medium was exchanged for fresh αMEM+
10%FBS containing 10 or 20 μM PD98059 or SB203580
and incubated for 48 h. After the incubation, the cells were
rinsed with ice-cold phosphate-buffered saline (PBS),
homogenized in 0.5 M Tris (pH 9.0) containing 0.9% NaCl
and 1% Triton X-100 on ice, and centrifuged at 12,000 g
for 15 min. ALPase activity in the resultant supernatants
was determined by the method of Bessey (Bessey et al.
1946) with some modifications. The enzyme reaction was
initiated with 0.5 mM p-NPP in 0.5 M Tris-HCl (pH 9.0)
containing 0.5 mM MgCl2 at 37°C and terminated by the
addition of a quarter volume of 1 M NaOH. The
concentration of p-NP generated was determined by
spectrophotometry at 410 nm, and the enzyme activity
was expressed as nmol p-NPP cleaved per minute per well.
Mineralization assay
Cells were inoculated at a density of 1×105 cells/well in
24-well multiplates and were cultured until confluent with
MEM containing 10% FBS. SaOS-2 cells were cultured in
complete αMEM containing 10% FBS, 50 μg/ml ascorbic
acid and 10 mM β-GP in the presence of 20 μM PD98059
or SB203580 for 10 days. The cells were fixed in 95%
ethanol for 15 min at 37°C, washed with PBS, and stained
with 1% alizarin red for 5 min at room temperature. DMSO
was added to control cultures.
Immunoblot analysis
SaOS-2 monolayer cultures were rinsed with ice-cold PBS
and lysed in ice-cold lysis buffer (50 mM Tris-HCl, pH 7.4,
containing 150 mM NaCl, 1% Triton X-100, 1% NP-40,
10 mM NaF, 100 μM leupeptin, 2 μg/ml aprotinin, and
1 mM phenylmethyl sulfonyl fluoride) on ice. Cell lysates
containing 10 μg of total protein in lysis buffer were
electrophoresed in 12% SDS-PAGE gels (READYGELS,
BIO-RAD) and the proteins were transferred to nylon
membranes. The membranes were blocked with 2% nonfat
dry milk in TBS overnight at 4°C and then incubated with a
1:200 dilution of anti-p-ERK1/2, ERK1/2, p-p38 or p38
antibodies. Horseradish peroxidase-conjugated goat anti-
rabbit or goat anti-mouse IgG were used as the secondary
antibodies at a 1:1,000 dilution. Bands were visualized by
using the ECL chemiluminescence detection method
(RPN2109, Amersham Biosciences, UK).
Quantitative real-time RT-PCR
Total RNAwas isolated using TRIzol reagent (Life Technol-
ogies Inc.), according to the manufacturer’s instructions.
Complementary DNA was generated from 1 μg of total
RNA using the First Strand cDNA Synthesis Kit (Invitrogen)
in a final volume of 20 μl. Real-time RT-PCR was performed
with a Light Cycler (Roche Molecular Biochemicals,
Mannheim, Germany) in Light Cycler capillaries using a
commercially available master mix containing Taq DNA
polymerase and SYBR-Green I deoxyribonucleoside triphos-
phates (Light Cycler DNA master SYBR-Green I, Roche
Molecular Biochemicals). After the addition of primers,
MgCl2 (3 mM), and template DNA to the master mix, 65
cycles of denaturation (95°C for 10 s), annealing, (55°C for
5 s) and extension (72°C for 10 s) were performed. Primers
used were the following: 5′-CAGACTGGCAACCTCAA
MEK inhibitor regulates osteosarcoma cell differentiation 109
GAA-3′ and 5′-GGAGGTCTTGGTGGTTTTGT-3′ for type
I collagen; 5′-CCCCGTGGCAACTCTATCTT-3′ and 5′-
CTGCGCCTGGTAGTTGTTGT-3′ for ALP; 5′-GAGGG
CAGCGAGGTAGTGAA-3′ and 5′-TCCTGAAAGCC
GATGTGGTC-3′ for osteocalcin; 5′-ATGCTAGACCTG
TATCGC and 5′-TCGTTTCTGGTAGTTCTTCC-3′for
BMP-2; and 5′-TGAACGGGAAGCTCACTGG-3′ and 5′-
TCCACCACCCTGTTGCTGTA-3′ for GAPDH. After the
completion of PCR amplification, a melting curve analysis
was performed. The fluorescence intensity of the double-
strand-specific SYBR Green I, reflecting the amount of
formed PCR product, was monitored at the end of each
elongation step. GAPDH mRNA levels were used to
normalize the cDNA content of the samples.
Immunofluorescence analysis
After growth on culture slides, SaOS-2 cells were washed
with PBS and fixed 20 min with cold methanol, and then
permeabilized in 0.1% NP-40 in PBS. After the fixed cells
had been washed three times with PBS, they were
incubated at 4°C overnight with the desired primary
antibody in 3% BSA-PBS. Then, the sections were washed
three times with PBS and thereafter reacted with fluorescein
isothiocyantate (FITC) or rodamine-conjugated anti-rabbit
or anti-mouse IgG serum in 3% bovine serum albumin
(BSA)-PBS for 1 h. The sections were finally washed three
times with PBS, and were mounted and viewed under a
fluorescence microscope (IX81, Olympus, Tokyo, Japan).
Statistical analysis
Data were analyzed by using the Fisher’s protected least
significant difference (Fisher’s PLSD) for analysis of multiple
group comparisons. Results were expressed as the mean±S.D.
p<0.05 was considered statistically significant.
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